PALM BEACH, Florida, November 17, 2016 /PRNewswire/ --
Biotech industry professionals have suggested that a significant part of the biotech rally of late may be a direct result of Trump's victory with a vague promise to reform the FDA and "put greater focus on the need of patients for new and innovative medical products." Biotech stocks with current and recent achievements in the markets include: Cellectar Biosciences, Inc. (NASDAQ: CLRB), Array BioPharma Inc. (NASDAQ: ARRY), Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), Amarin Corporation plc (NASDAQ: AMRN) and Abbott Laboratories (NYSE: ABT).
Cellectar Biosciences, Inc. (NASDAQ: CLRB), an oncology-focused, clinical stage biotechnology company, today announces that following the successful conjugation of multiple, natural product cytotoxic molecules developed by Pierre Fabre to Cellectar's PDC delivery platform, it has initiated in vivo studies for a variety of solid tumors. Harnessing a selection of linkers to attach the cytotoxic molecules to the PDC platform, the company has constructed a series of novel compounds specifically designed for improved tumor targeting. This research collaboration falls under the company's CLR CTX programs, geared to convert non-targeted cytotoxic agents into targeted cancer treatments when combined with Cellectar's proprietary delivery system. The drug's targeting enhancement is designed to further improve efficacy and reduce adverse events.
Read the full Cellectar Biosciences (CLRB) Press Release at: http://marketnewsupdates.com/news/clrb.html
As part of the Pierre Fabre research collaboration, Cellectar has already completed a series of in vitro studies with the newly created compounds, and is currently compiling early efficacy data. Cellectar will then initiate additional in vitro and in vivo studies in melanoma, lung, and colon cancers, as well as in additional solid tumors.
"We are excited by the rapid advancement of these programs and look forward to sharing data from our development work with Pierre Fabre," said Jim Caruso, president and CEO of Cellectar Biosciences. "This partnership is an excellent example of the power of our business model, a cost-efficient system with the potential to generate high-yielding assets. In parallel, we continue to make significant progress on our lead radiotherapeutic PDC, CLR 131 for the treatment of relapsed/refractory multiple myeloma, including our ongoing Phase I and our impending NCI-supported Phase II clinical trial in selected hematologic malignancies."
In other Biotech market performances and developments of note:
Array BioPharma Inc. (NASDAQ: ARRY) closed up slightly on Wednesday closing at $7 trading over 5.42 Million shares by the market close. Array BioPharma retains exclusive rights to binimetinib and encorafenib in the U.S., Japan, Canada, Korea and Israel which was recently reported Binimetinib plus encorafenib meets primary endpoint with statistically significant advantage on median PFS of 14.9 months versus 7.3 months for vemurafenib monotherapy. Read more at http://finance.yahoo.com/news/columbus-phase-3-study-results-160000344.html
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a clinical stage biopharmaceutical company focused on the global immunology market, on Wednesday highlighted additional findings from its global Phase IIb AURA study of voclosporin in the treatment of lupus nephritis (LN). The abstract was presented at the American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Washington, D.C. during the Late-Breaking News session on November 15, 2016.
Amarin Corporation plc (NASDAQ: AMRN) closed up at $3.45 on Wednesday trading over 4.38 Million shares traded by the market close. AMRN this week announced an oral presentation that was held at the American Heart Association Scientific Sessions 2016, New Orleans on November 14, 2016 that further characterized the efficacy and safety of Vascepa® (icosapent ethyl) in statin-treated women with persistent high triglyceride levels.
Abbott Laboratories (NYSE: ABT) closed up 14 cents at $39.95 on Wednesday trading over 8.8 Million shares traded by the market close. ABT announced this month that the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the company's Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people in Japan with coronary artery disease. Absorb is the only fully dissolving heart stent approved in Japan for the treatment of heart disease, one of the leading causes of death in Japan and worldwide. An estimated 1.73 million people in Japan (population:127 million) have heart disease, and approximately 71.7 thousand people die each year from coronary artery disease, making it the secondary leading cause of death in the country annually. Worldwide, more than 7.4 million people die of heart disease each year.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated one thousand seven hundred dollars for news coverage of the current press release issued by Cellectar Biosciences, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Media Contact email: [email protected] , +1-561-325-8757